araag2/HINT huggingface dataset:
Clinical trial NCT01349868 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: pt005 mdi, formoterol fumarate 12 μg (foradil® aerolizer®), formoterol fumarate 24 μg (foradil® aerolizer®)
SMILES: COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1, COC1=CC=C(CC(C)NCC(O)C2=CC(NC=O)=C(O)C=C2)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 80 years of age

          -  Clinical history of COPD with airflow limitation that is not fully reversible

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  A measured post- bronchodilator FEV1/FVC ratio of < or = 0.70

          -  A measured post- bronchodilator FEV1 > or = 750ml or 30% predicted and < or = 80% of
             predicted normal values

          -  Able to change COPD treatment as required by protocol

          -  Demonstratead reversibility to short acting beta agonist (Ventolin HFA) (> 12% and
             >150 mL improvement in baseline FEV1 approximately 30 minutes following administration
             of 4 puffs of Ventolin HFA or > 200 mL improvement in baseline FEV1 30 minutes
             following administration of 2 puffs of Ventolin HFA)

        Key Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 3 months of Screening

          -  Clinically significant medical conditions that preclude participation in the study
             (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma,
             symptomatic prostatic hypertrophy)

          -  Cancer that has not been in complete remission for at least 5 years

          -  Treatment with investigational study drug or participation in another clinical trial
             or study within the last 30 days or 5 half lives

        Other inclusion/exclusion criteria as defined by the protocol
Clinical trial NCT00372996 (phase 2, status: terminated)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: cp-751,871, exemestane, exemestane, fulvestrant
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(O)C=C3C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@@]21[H]
Reason stopped: 
    this study was closed to enrollment as of 13 may 2011 due to business reasons. premature
    closure was not prompted by any safety or efficacy concerns.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women with a diagnosis of hormone receptor positive advanced breast
             cancer

          -  HbA1c <5.7%

        Exclusion Criteria:

          -  Previous treatment for advanced disease
Clinical trial NCT00553488 (phase 2, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: regular insulin (humulin), insulin lispro (humalog)
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes for 1-15 years, on multiple daily injections (MDI) or insulin pump
             (CSII) in stable control with HbA1c <= 9.0%.

          -  Able to attend clinic for 5 different days

        Exclusion Criteria:

          -  BMI > 32 kg/m2

          -  Evidence of gastroparesis or impaired renal function or lipodystrophy
Clinical trial NCT00717405 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: standard chemotherapy, bevacizumab [avastin], trastuzumab [herceptin]
SMILES: [Ta], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult females, >=18 years of age;

          -  inflammatory breast cancer;

          -  HER2-positive tumors;

          -  performance status 0-2.

        Exclusion Criteria:

          -  metastases;

          -  previous treatment with chemotherapy, radiation therapy or hormone therapy for a
             breast tumor;

          -  clinically significant cardiovascular disease, or history of thrombotic disorders.
Clinical trial NCT00602680 (phase 2, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: ssr180711c, donepezil, placebo
SMILES: O=S(=O)(C1=CC=CC=C1)C1=CN=C2C(C=CC=C2N2CCNCC2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    insufficient expected benefit risk
  
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with diagnosis of mild AD

        Exclusion Criteria:

          -  Concomitant or previous treatment by acetylcholinesterase inhibitors and/or memantine

          -  Medical condition which may interfere with the study

          -  History of epileptic seizures

          -  Lens opacity

          -  Lack of reliable caregiver

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00712725 (phase 2, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: mk3207- 2.5 mg, mk3207- 5 mg, mk3207- 10 mg, mk3207- 20 mg, mk3207- 50 mg, mk3207- 100 mg, comparator: placebo (unspecified)
SMILES: FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1, FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1, FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1, FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1, FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1, FC1=CC(=CC(F)=C1)[C@@H]1CNC2(CCCC2)C(=O)N1CC(=O)NC1=CC=C2C[C@]3(CC2=C1)C(=O)NC1=C3C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and Women from 18 to 65 years of age

          -  1+ year history of migraine that typically last from 4 to 72 hours if untreated

          -  Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months

          -  Not pregnant or planning to become pregnant in next 6 months

        Exclusion Criteria:

          -  Pregnant or breast-feeding, or planning to become pregnant in next 6 months

          -  Cannot distinguish migraine attacks from tension type headaches

          -  Migraines are mild or resolve without medication in less than 2 hours

          -  More than 15 headache-days per month or have taken medication on more than 10 days per
             month in the last 3 months

          -  Basilar type or hemiplegic migraine headaches

          -  More than 50 years old when migraines began

          -  History of cardiovascular disorder within last 6 months
Clinical trial NCT00210314 (phase 2, status: completed)
Conditions: lymphoma, b cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: high dose methotrexate, high dose cytarabine
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          1. Histological or cytological diagnosis of non-Hodgkin's lymphoma.

          2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology
             examination or vitrectomy.

          3. Disease exclusively localized into the central nervous system, cranial nerves or eyes.

          4. Untreated patients (patients treated with steroids alone are eligible).

          5. At least one measurable lesion.

          6. Age 18 - 75 years.

          7. ECOG performance status < 3

          8. HBsAg-negative and Ab anti-HCV-negative serologic status.

          9. No known HIV disease or immunodeficiency.

         10. Adequate bone marrow (PLT > 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal
             (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total
             serum bilirubin < 3 mg/dL, AST/ALT and gGT < 2 per upper normal limit value).

         11. No previous or concurrent malignancies with the exception of surgically cured cervical
             intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and
             of other cancers without evidence of disease since at least 5 years (patients with a
             previous lymphoma diagnosis will be excluded).

         12. Absence of any familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule.

         13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive
             measures during study participation for sexually active patients of childbearing
             potential.

         14. No concurrent treatment with other experimental drugs.

         15. Informed consent signed by the patient before registration
Clinical trial NCT00623974 (phase 2, status: terminated)
Conditions: hypocalcemia
ICD codes: E83.51, P71.1, P71.0
Drugs: teriparatide (forteo), calcium, calcitriol
SMILES: [Ca], C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Reason stopped: 
    terminated due to slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients who are scheduled for total thyroidectomy, and/or extensive neck dissections
             (pharyngectomy, laryngectomy, unilateral/bilateral/central neck, and/or mediastinal
             lymph node neck dissections).

          2. Patients who develop, between 18-24 hours after surgery, hypocalcemia as defined by a
             corrected serum calcium <8.0mg/dL. [Corrected serum calcium (mg/dL) = Measured calcium
             + (4-albumin) x 0.8]

        Exclusion Criteria:

          1. Patients who have jejunal tubes

          2. Patients <18 years old.

          3. Treatment with teriparatide or calcitriol (Rocaltrol) within 1 month prior to surgery

          4. Treatment with a bisphosphonate within 3 months prior to surgery

          5. Hypercalcemia (corrected serum calcium >10.5mg/dL) or hypocalcemia (corrected serum
             calcium <8.4mg/dL) on preoperative labs (drawn within 21 days of surgery)

          6. Paget's disease of bone

          7. Elevated alkaline phosphatase > institutional upper limit of normal (ULN)

          8. History of external beam irradiation to the skeleton

          9. History of skeletal metastases

         10. History of untreated gout

         11. History of unstable angina pectoris

         12. History of symptomatic orthostatic hypotension

         13. Pregnancy (as screened by a serum/urine pregnancy test) or breast-feeding. Female
             subjects of childbearing potential must have a negative pregnancy test within 7 days
             of surgery. Postmenopausal women (absence of menses for 12 months) or women with
             history of hysterectomy or bilateral oophorectomy will not be required to have a
             pregnancy test. Male and female patients of reproductive potential must agree to
             utilize an effective form of contraception throughout the study period. The definition
             of effective contraception will be based on the judgment of the Investigator or
             designated associate.

         14. Hepatic and renal dysfunction defined by the following parameters: (a) Serum AST
             (SGOT) and ALT (SGPT) > 3 times the institutional ULN, (b) Total serum bilirubin > 2
             times the institutional ULN, (c) Serum creatinine > 1.5mg/dL or estimated creatinine
             clearance < 40mL/min

         15. Psychiatric illness or social situation that would limit compliance with study
             requirements

         16. Concomitant use of digoxin

         17. Patients may not be receiving any other investigational agents or have participated in
             any investigational drug study within 28 days preceding the start of study treatment.
Clinical trial NCT01764854 (phase 2, status: completed)
Conditions: end stage renal disease, chronic kidney disease stage 5, esrd
ICD codes: N18.6, I12.0, I13.11, I13.2, N18.5, I12.0, I13.11, I13.2
Drugs: azd1722 (in-patient), placebo (in-patient), azd1722 (out-patient), placebo
SMILES: CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C[C@@H](C2=CC(=CC=C2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)C2=CC(=CC=C2)[C@@H]2CN(C)CC3=C2C=C(Cl)C=C3Cl)C2=C(C1)C(Cl)=CC(Cl)=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females aged 18 to 80 years, inclusive;

          -  Body mass index between 18 and 45 kg/m2, inclusive;

          -  Ambulatory (≥ 6 months) maintenance hemodialysis;

          -  Stable dialysis treatment regimen 3x/week for ≥ 2 months prior to screening visit.

        Exclusion Criteria:

          -  Currently taking diuretic medication;

          -  Has a urine production of ≥ 200 ml/day (based on a 24-hour measurement starting on Day
             -1 and completed prior to randomization);

          -  Predialysis systolic BP >200 mmHg or diastolic BP >110 mmHg on two successive
             occasions during the 2-week run-in period;

          -  Predialysis SBP < 110 mmHg on two successive occasions during the 2-week run-in period
Clinical trial NCT00714259 (phase 2/phase 3, status: terminated)
Conditions: multiple myeloma, cll / sll, non hodgkin's lymphoma, waldenstroms, mantle cell lymphoma
ICD codes: C90.01, C90.02, C90.00, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: fludarabine
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    accrual goals could not be met within a timely manner
  
Eligibility criteria:

        Inclusion Criteria:

          -  Stage II or III non-progressive disease Multiple Myeloma.

          -  CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or
             complete response with non-progressive disease.

          -  ≤ 70 years old.

          -  Eligible and willing HLA matched related donor.

          -  Bilirubin <2xULN.

          -  ALT and AST <3xULN.

          -  LVEF > 40%.

          -  Creatinine Clearance >40mL/min.

          -  Pulmonary function DLCO corrected to ≥ 70%.

          -  Minimum performance score of 70%.

          -  Platelet count >130 x103 micro L.

          -  LDH ≤1.5xULN.

          -  No proceeding co-morbid condition that significantly increases the risk of severe
             regimen related toxicity.

          -  No uncontrolled infections.

        Exclusion Criteria:

          -  Age >70 years old.

          -  Performance status <70%.

          -  Uncontrolled infections or is HIV positive

          -  Prior malignancies that are felt to have a <80% probability of being cured.

          -  Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12
             months following transplant.

          -  Prior Allograft

          -  History of rapidly growing disease at diagnosis or at any progression or have MDS.

          -  No eligible and willing HLA matched donor.
Clinical trial NCT00537355 (phase 2, status: completed)
Conditions: rhinitis, allergic, seasonal
ICD codes: J30.2
Drugs: histamine
SMILES: NCCC1=CNC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Is willing and able to give signed informed consent, and must have provided this
             consent.

          -  Has a clinical history of seasonal allergic rhinitis with seasonal nasal allergy
             symptoms during each of the last 2 ragweed allergy seasons.

          -  Has documentation of a positive skin test to ragweed allergen within 12 months of
             screening.

          -  Has minimum qualifying symptom scores at the last visit of the Pre-Treatment EEC
             sessions (Visit 5, Day 4).

          -  If female of childbearing potential, is not pregnant and is consistently using an
             acceptable birth control method.

          -  Is normally active and otherwise judged to be in good health on the basis of medical
             history, physical examination and routine laboratory tests.

        Exclusion Criteria:

          -  A woman who is pregnant, breastfeeding, or planning a pregnancy.

          -  Has a history of more than mild asthma that requires the use of a daily inhaled or
             oral corticosteroid, leukotriene inhibitor, or cromolyn; or a daily inhaled short or
             long acting β-agonist.

          -  Has had any hospital admissions for asthma, a recent (within the past 12 months)asthma
             exacerbation that required either oral or inhaled corticosteroids, or a prior history
             of unstable asthma.

          -  Has received immunotherapy within the last 2 years that has contained ragweed pollen
             extract.

          -  Has previously participated in a clinical trial with TOLAMBA or another ragweed-based
             immunotherapy.

          -  Has received immunotherapy for any allergens within 30 days prior to Visit 1.

          -  Has the need for use of antihistamines or corticosteroids on a regular basis (systemic
             or topical).

          -  Has received anti-immunoglobulin E (IgE) antibody (Xolair®) within the past 12 months.

          -  Is currently taking monoamine oxidase (MAO) inhibitors.

          -  Has taken any systemic corticosteroids, immunomodulators, or immune suppressive
             medications within 4 weeks prior to Visit 1.

          -  Has taken any antihistamine within 7 days prior to Visit 1 skin testing.

          -  Requires use of β-adrenergic blockers or other agents that may interfere with the use
             of adrenaline.

          -  Known current alcohol or drug abuse.

          -  Current participation in another clinical study involving an investigational drug or
             device, or participation in such a study within 30 days prior to Visit 1.

          -  Has a history of generalized anaphylaxis requiring medical attention.

          -  Has moderate or severe allergy symptoms at Visit 1.
Clinical trial NCT00415038 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: rostafuroxin, rostafuroxin, rostafuroxin, rostafuroxin, rostafuroxin
SMILES: C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1, C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@]2(O)C1=COC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with grade 1 or 2 of essential hypertension

          -  Less than 3 risk factors (age > 55 if male, smoking, dyslipidemia, family history of
             CV disease occurring before 55 years in men and 65 in women

          -  Naive patients or currently on monotherapy or one combination tablet

          -  SBP between 140 and 169 mmHg

        Exclusion Criteria:

          -  Atrial fibrillation or left or right VBBB

          -  Left ventricular hypertrophy

          -  Significant renal or hepatic disease

          -  Obesity > 30kg/m2

          -  Diabetes mellitus
Clinical trial NCT00520572 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: azd9056, etanercept, placebo
SMILES: OCCCNCCCC1=CC(C(=O)NCC23CC4CC(CC(C4)C2)C3)=C(Cl)C=C1, [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6
             tender/painful joints, and either have (blood tests) elevated erythrocyte
             sedimentation rate (ESR) or C-reactive protein (CRP). At least one of the following:
             documented history and current presence of positive rheumatoid factor (blood test),
             baseline radiographic erosion.

        Be receiving either oral (tablets) or subcutaneous/intramuscular (injection) methotrexate
        for at least 6 months prior to randomisation.

        Exclusion Criteria:

          -  Any other inflammatory disease in addition to RA that may interfere with the study
             (e.g. polymyalgia rheumatica, giant cell arteritis, reactive arthritis, e t c).
             Current chronic pain disorders including fibromyalgia and chronic fatigue syndromes.
             Persistently abnormal liver function enzymes (blood test).